Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma
Hamilton, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Initiative is Nuance’s first step in penetrating Chinese market with BentrioTMDensely populated...
COVID-19
Oncotelic Publishes SNO 27th Annual Meeting Presentation Materials
AGOURA HILLS, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer...
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with encorafenib and cetuximab in BRAF V600E-mutant metastatic colorectal...
AUM Biosciences Receives FDA Orphan Drug Designation for AUM302 for the Treatment of Neuroblastoma
AUM302 has potential to be the first multi-kinase inhibitor class of drug in NeuroblastomaSINGAPORE and BETHESDA, Md., Nov. 30, 2022...
Shineco, Inc. Attends MEDICA 2022 Düsseldorf Germany
Shineco, Inc. Dr. Marvin Liu (second person from the left) introduced products to customers on siteBEIJING, Nov. 29, 2022 (GLOBE...
Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development
Avero Diagnostics to Develop and Commercialize, Enabling Potential Future Revenue for Biora TherapeuticsSAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) --...
Assure to Attend Investor Conferences in December 2022
DENVER, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative...
ProSomnus Reports Third Quarter Financial Results and Provides Corporate Update
Generated record quarterly revenues, and expects merger with Lakeshore Acquisition I Corp. to close in the fourth quarter of 2022...
Interim Data from Ambrx’s Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium
Investigators to present efficacy and safety data of ARX788 treatment in patients with HER2+ metastatic breast cancer who have progressed...
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical...
Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies
Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience as an in vitro diagnostics...
Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia
Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via nasal sprayWARREN, N.J., Nov. 29,...
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
Transaction proceeds, together with cash on-hand, expected to fund operations through late 2023/early 2024, including potential FDA approval of MydCombi™NEW...
POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy
Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant...
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
DEVON, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China
WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company...
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High Risk of Disease Progression, Regardless...
Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease
Risk scoring by KidneyIntelX resulted in a 4.5-fold increase in new drug prescriptions (for SGLT2 inhibitors) for high risk compared...
Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
FDA decision based on new Phase 1b data: Objective Response Rate (ORR) of 57% and median Progression-Free Survival (PFS) of...
BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy
Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe illness and faster recovery in...